Evotec receives EUR2m milestone payment from Boehringer

The multi-target drug discovery alliance was originally signed in 2004 for the co-identification and co-development of preclinical development candidates targeting various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases.

The milestone reached was on the transition of an oncology programme into lead optimisation.

As per the terms of the pact, Boehringer Ingelheim earned full ownership and global responsibility to develop, manufacture and commercialize the compounds identified under the collaboration.

However, Evotec receives ongoing research payments and preclinical milestones.

Evotec chief operating officer Mario Polywka said this is the 12th milestone achieved as part of this alliance with Boehringer Ingelheim and the third against an oncology target.

"We are now in our eighth year of this collaboration and this milestone again validates the strength of the joint Evotec –Boehringer research groups as they drive new drug candidates to the clinic," Polywka said.